Slovenia - Sloven - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lek d.d. - amoksicilin - prašek za peroralno suspenzijo - amoksicilin 100 mg / 1 ml - amoksicilin

Slovenia - Sloven - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lek d.d. - amoksicilin - prašek za peroralno suspenzijo - amoksicilin 25 mg / 1 ml - amoksicilin

Slovenia - Sloven - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

salus, veletrgovina, d.o.o. - natrijev benzoat; natrijev fenilacetat - raztopina za infundiranje - natrijev benzoat 100 mg / 1 ml  natrijev fenilacetat100 mg / 1 ml; natrijev fenilacetat 100 mg / 1 ml - razna zdravila za bolezni prebavil in presnove

Slovenia - Sloven - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

krka, d.d., novo mesto - askorbinska kislina (vitamin c); cianokobalamin (vitamin b12); vseracemni-alfa-tokoferilacetat; folna kislina (vitamin b9); holekalciferol (vitamin d3); kalcijev pantotenat; nikotinamid; piridoksinijev klorid; riboflavin (vitamin b2); tiaminijev nitrat; vitamin a - obložena tableta - askorbinska kislina (vitamin c) 60 i.e. / 1 tableta  cianokobalamin (vitamin b12)0,003 i.e. / 1 tableta  vseracemni-alfa-tokoferilacetat10 i.e. / 1 tableta  folna kislina (vitamin b9)0,4 i.e. / 1 tableta  holekalciferol (vitamin d3)200 i.e. / 1 tableta  kalcijev pantotenat5 i.e. / 1 tableta  nikotinamid13 i.e. / 1 tableta  piridoksinijev klorid2 i.e. / 1 tableta  riboflavin (vitamin b2)1,2 i.e. / 1 tableta  tiaminijev nitrat1 i.e. / 1 tableta  vitamin a5000 i.e. / 1 tableta; cianokobalamin (vitamin b12) 0,003 i.e. / 1 tableta  vseracemni-alfa-tokoferilacetat10 i.e. / 1 tableta  folna kislina (vitamin b9)0,4 i.e. / 1 tableta  holekalciferol (vitamin d3)200 i.e. / 1 tableta  kalcijev pantotenat5 i.e. / 1 tableta  nikotinamid13 i.e. / 1 tableta  piridoksinijev klorid2 i.e. / 1 tableta  riboflavin (vitamin b2)1,2 i.e. / 1 tableta  tiaminijev nitrat1 i.e. / 1 tableta  vitamin a5000 i.e. / 1 tableta; vseracemni-alfa-tokoferilacetat 10 i.e. / 1 tableta  folna kislina (vitamin b9)0,4 i.e. / 1 tableta  holekalciferol (vitamin d3)200 i.e. / 1 tableta  kalcijev pantotenat5 i.e. / 1 tableta  nikotinamid13 i.e. / 1 tableta  piridoksinijev klorid2 i.e. / 1 tableta  riboflavin (vitamin b2)1,2 i.e. / 1 tableta  tiaminijev nitrat1 i.e. / 1 tableta  vitamin a5000 i.e. / 1 tableta; folna kislina (vitamin b9) 0,4 i.e. / 1 tableta  holekalciferol (vitamin d3)200 i.e. / 1 tableta  kalcijev pantotenat5 i.e. / 1 tableta  nikotinamid13 i.e. / 1 tableta  piridoksinijev klorid2 i.e. / 1 tableta  riboflavin (vitamin b2)1,2 i.e. / 1 tableta  tiaminijev nitrat1 i.e. / 1 tableta  vitamin a5000 i.e. / 1 tableta; holekalciferol (vitamin d3) 200 i.e. / 1 tableta  kalcijev pantotenat5 i.e. / 1 tableta  nikotinamid13 i.e. / 1 tableta  piridoksinijev klorid2 i.e. / 1 tableta  riboflavin (vitamin b2)1,2 i.e. / 1 tableta & - multivitamini in drugi minerali ter kombinacije

Uni Eropa - Sloven - EMA (European Medicines Agency)

merck sharp and dohme b.v - posakonazol - candidiasis; mycoses; coccidioidomycosis; aspergillosis - antimikotiki za sistemsko uporabo - noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 in 5. 1):- invasive aspergillosisnoxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections  4. 2 in 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. refractoriness je opredeljena kot napredovanje okužbe ali neuspeh za izboljšanje po najmanj 7 dni pred terapevtskih odmerkih učinkovito protiglivično zdravljenje. noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4. 2 in 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 in 5. 1):- invasive aspergillosisnoxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adult and paediatric patients from 2 years of age (see sections 4. 2 in 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. refractoriness je opredeljena kot napredovanje okužbe ali neuspeh za izboljšanje po najmanj 7 dni pred terapevtskih odmerkih učinkovito protiglivično zdravljenje. noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following adult and paediatric patients from 2 years of age (see sections 4. 2 in 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (gvhd) and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil gastro resistant powder and solvent for oral suspension is indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age (see sections 4. 2 in 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. refractoriness je opredeljena kot napredovanje okužbe ali neuspeh za izboljšanje po najmanj 7 dni pred terapevtskih odmerkih učinkovito protiglivično zdravljenje. noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2  years of age:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high  risk of developing invasive fungal infections;- haematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high  risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5. 1):- invazivne aspergillosis pri bolnikih z boleznijo, ki je neodzivna, da amphotericin b ali itraconazole ali pri bolnikih, ki ne prenašajo teh zdravil;- fusariosis pri bolnikih z boleznijo, ki je neodzivna, da amphotericin b ali pri bolnikih, ki so nestrpne amphotericin b;- chromoblastomycosis in mycetoma pri bolnikih z boleznijo, ki je neodzivna, da itraconazole ali pri bolnikih, ki so nestrpne itraconazole;- coccidioidomycosis pri bolnikih z boleznijo, ki je neodzivna, da amphotericin b, itraconazole ali fluconazole ali pri bolnikih, ki ne prenašajo teh zdravil;- Žrela kandidoza: kot prvo linijo zdravljenja pri bolnikih, ki imajo hude bolezni ali so immunocompromised, v kateri je odziv na aktualne terapija je pričakovati, da bo slaba. refractoriness je opredeljena kot napredovanje okužbe ali neuspeh za izboljšanje po najmanj 7 dni pred terapevtskih odmerkih učinkovito protiglivično zdravljenje. noxafil oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.

Slovenia - Sloven - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

bayer d.o.o. - acetilsalicilna kislina; psevdoefedrinijev klorid - zrnca za peroralno suspenzijo - acetilsalicilna kislina 500 mg / 1 vrečica  psevdoefedrinijev klorid30 mg / 1 vrečica; psevdoefedrinijev klorid 30 mg / 1 vrečica - acetilsalicilna kislina

Slovenia - Sloven - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

aurobindo pharma limited - amoksicilin; klavulanska kislina - filmsko obložena tableta - amoksicilin 500 mg / 1 tableta  klavulanska kislina125 mg / 1 tableta; klavulanska kislina 125 mg / 1 tableta - amoksicilin in zaviralec laktamaz beta

Slovenia - Sloven - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

aurobindo pharma limited - amoksicilin; klavulanska kislina - filmsko obložena tableta - amoksicilin 875 mg / 1 tableta  klavulanska kislina125 mg / 1 tableta; klavulanska kislina 125 mg / 1 tableta - amoksicilin in zaviralec laktamaz beta

Slovenia - Sloven - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

aurobindo pharma limited - amoksicilin; klavulanska kislina - filmsko obložena tableta - amoksicilin 500 mg / 1 tableta  klavulanska kislina125 mg / 1 tableta; klavulanska kislina 125 mg / 1 tableta - amoksicilin in zaviralec laktamaz beta

Slovenia - Sloven - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

aurobindo pharma limited - amoksicilin; klavulanska kislina - filmsko obložena tableta - amoksicilin 875 mg / 1 tableta  klavulanska kislina125 mg / 1 tableta; klavulanska kislina 125 mg / 1 tableta - amoksicilin in zaviralec laktamaz beta